Australian Researchers Kill the Malaria Parasite with 'Salt Overload' 15 Feb 2013
The Global Dispatch In a paper published in the latest edition of Cell Host & Microbe, Dr. Natalie Spillman with the Research School of Biology (RSB) showed that the malaria parasite has at its surface a protein that serves as a molecular salt pump, pushing sodium ions out of the parasite.
By blocking the pump using a potent class of antimalarials, the spiroindolones, researchers believe they can kill the dreaded parasite by causing it to fill rapidly with salt, causing "salt overload".
"The malaria parasite's salt pump would seem to be an Achilles heel for the parasite, particularly vulnerable to attack. Knowing this, we can now look for other drugs that block this pump. We can also start to investigate how the parasite might be able to change the shape of the pump and thereby develop resistance to this class of drugs. Both of these aspects are going to be very important in our ongoing battle with the parasite", according to RSB Director Professor Kiaran Kirk, the senior author on the study.
The spiroindolones are the first genuinely novel class of chemicals to be tested in malaria patients for over 20 years, according to a ANU news release.
"We desperately need new antimalarials and the spiroindolones, now in advanced clinical trials, are looking extremely promising," Professor Kirk said.
http://www.theglobaldispatch.com/australian-researchers-kill-the-malaria-parasite-with-salt-overload-92652/The Global Dispatch In a paper published in the latest edition of Cell Host & Microbe, Dr. Natalie Spillman with the Research School of Biology (RSB) showed that the malaria parasite has at its surface a protein that serves as a molecular salt pump, pushing sodium ions out of the parasite.
By blocking the pump using a potent class of antimalarials, the spiroindolones, researchers believe they can kill the dreaded parasite by causing it to fill rapidly with salt, causing "salt overload".
"The malaria parasite's salt pump would seem to be an Achilles heel for the parasite, particularly vulnerable to attack. Knowing this, we can now look for other drugs that block this pump. We can also start to investigate how the parasite might be able to change the shape of the pump and thereby develop resistance to this class of drugs. Both of these aspects are going to be very important in our ongoing battle with the parasite", according to RSB Director Professor Kiaran Kirk, the senior author on the study.
The spiroindolones are the first genuinely novel class of chemicals to be tested in malaria patients for over 20 years, according to a ANU news release.
"We desperately need new antimalarials and the spiroindolones, now in advanced clinical trials, are looking extremely promising," Professor Kirk said.
this story also covered at:
http://www.fightingmalaria.org/news.aspx?id=1923
No comments:
Post a Comment